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doi:10.1016/j.ejvs.2010.09.025Abstract Aim: The aim of this article was first to review the complex pathophysiological
mechanisms responsible for symptoms and signs of primary chronic venous disease (CVD) that
allow the identification of targets for pharmacological treatment. The results of CVD treat-
ment with venoactive drugs (VADs) were emphasised and presented in the form of recommen-
dations. The last section raises key questions to be answered to improve protocols for good
clinical trials and to draw up future guidelines on these agents.
Methods: The literature has been reviewed here using PubMed and Embase.
Results: Venous hypertension appears to underlie all clinical manifestations of primary CVD.
Inflammation is key in wall remodelling, valve failure and subsequent venous hypertension.
Changes in the haemodynamics of veins are transmitted to the microcirculation, resulting in
capillary alteration leading to oedema, skin changes and eventually venous ulceration. Venous
symptoms may be the result of interplays between pro-inflammatory mediators and nerve
fibres located in the venous wall. Therefore, venous inflammation constitutes a promising ther-
apeutic target for pharmacological intervention, and some available VADs could attenuate
various elements of venous inflammation. Based on recent studies, reviews and guidelines,
tentative recommendations for the use of VADs were proposed and strong recommendations
were given to two of them (micronised purified flavonoid fraction and oxerutins).
Conclusion: VADs should be accorded a better role in the management of CVD. However, larger
and more definitive clinical trials are needed to improve the existing recommendations.
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This article addresses the drug treatment of chronic venous
disease (CVD) of primary aetiology. Primary CVD is defined
as morphological and functional abnormalities of the
venous system of long duration, manifested by symptoms or
signs or both, indicating the need for investigation and/or
care.1 This is a common condition with a major impact on
the health-care system due to its high prevalence,2 not to
mention the human impact in terms of worsened quality of
life (QoL). Unlike secondary CVD, which is the result of
thrombosis, the origin of primary CVD is unknown.3
There is a broad range of symptoms and signs associated
with primary CVD, the most obvious of which are varicose
veins and venous leg ulcers, but which also include oedema
and skin changes (venous eczema, ankle skin pigmentation,
atrophie blanche and lipodermatosclerosis).
Clinical presentations ofCVDcanbedescribedaccording to
the clinical, etiologic, anatomical and pathophysiological
(CEAP)classification,whichprovidesanorderly framework for
communication and diagnosis.3,4 The clinical signs in the
affected legs are categorised into seven classes designated
C0eC6 (Table 1). Leg symptoms associated with CVD include
tingling, aching, burning, pain, muscle cramps, sensation of
swelling, sensations of throbbing or heaviness, itching skin,
restless legs, leg tiredness and/or fatigue.1 Although not
pathognomonic, these may be suggestive of CVD, particularly
if they are exacerbated by heat or dependency during the
course of the day and relievedwith leg rest and/or elevation.1
Limbs categorised in any clinical classmay be symptomatic (S)
or asymptomatic (A). CVD encompasses the full spectrum of
signs and symptoms associated with classes C0seC6, whereas
the term ‘chronic venous insufficiency’ (CVI) is generally
restricted todiseaseofgreater severity (i.e., classesC3eC6).1
The last revision of the CEAP classification in 2004
included a new descriptordndfor the E, A and P of the CEAP
classification, when no anomaly is found in aetiology,
anatomy or pathophysiology of the disease.4 This introduced
newcategories such as C0s (‘symptoms only’), En, An, Pn (‘no
aetiology, no location, no pathophysiology identified’),
reflecting those subjects complaining from leg symptoms
before appearance of any sign, reflux or even obstruction.
The latter is usually difficult to identify. These patients are
frequently encountered in primary care practice andTable 1 Revised CEAP Clinical Classification of Chronic Venous
Clinical class Description 4
C0 No visible or palpable signs of ve
C1 Telangiectases or reticular veins
 Telangiectases defined by dil
 Reticular veins defined by di
C2 Varicose veins distinguished from
C3 Edema
C4 Changes in skin and subcutaneou
define the differing severity of v
 C4a, Pigmentation or eczema
 C4b, Lipodermatosclerosis or
C5 Healed venous ulcer
C6 Active venous ulcerrepresent the largest target population for venoactive drug
(VAD) treatment.
Understanding the pathophysiology of a disease state is
basic to effective treatment. Therefore, the aim of this
article is first to review the complex molecular processes set
in motion by haemodynamic pathology in CVD that warrant
pharmacological treatment. Then, we will emphasise the
results of such treatment and, more particularly, of VADs.
The last section will deal with controversies about this type
of treatment, the lack of data that needs to be addressed by
future studies and the key questions to be answered to draw
up future guidelines on pharmacological agents.
Pathophysiology of Primary CVD
Primary CVD is the result of increased and unabated venous
hypertension caused mostly by reflux through incompetent
valves, and sometimes by primary non post-thrombotic
obstruction and reflux.5 Venous hypertension is central to
alterations mostly in superficial veins (less frequently in
deep veins), in capillaries and, eventually, in skin. We will
endeavour to outline these three aspects of pathogenetic
mechanisms of CVD. Secondary CVD will intentionally not
be broached in the present review.
Valve and vein wall changes
Valves are present in both superficial and deep venous
systems to ensure that blood flows in a single direction,
from the superficial to the deep system, towards the heart
and against gravity.6 Damage to and alterations in the
saphenous vein valves are more frequently seen in varicose
than in non-varicose veins.7,8 The causes of such valve
failure are still under investigation, and several theories
have been put forward. It has been postulated that valvular
dysfunction causing reflux was the initial pathological
change in CVD.7,9 This hypothesis has been challenged
recently, and evidence seems to favour pre-existing weak-
ness in the vessel wall, which produces dilation and, in
turn, causes secondary valvular incompetence.6,10
Histologic and ultrastructural studies of varicose veins
have found structural changes in the vein wall. Intimal
hyperplasia and areas of hypertrophy with increased collagenDisease of the Leg.4
nous disease
ated intradermal venules <1 mm diameter
lated, nonpalpable, subdermal veins 3 mm in diameter
reticular veins by a diameter of 3 mm or more
s tissue secondary to CVD divided into 2 subclasses to better
enous disease
atrophie blanche
Figure 2 Schematic illustration of key events that may lead
to valve damage in primary venous disease; inflammatory gene
expression in the endothelium may be induced by a shift in
venous hydrostatic pressure and fluid shear stress. This
supports leukocyte rolling, adhesion, and migration together
with free radical formation, apoptosis, and tissue necrosis. In
the process, macrophages become the instruments of tissue
damage.
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smooth muscle cells (SMCs) and reduced extracellular matrix
(ECM).6,7 Degradation of ECM proteins is caused by an array of
proteolytic enzymes including matrix metalloproteases
(MMPs). The production of MMPs is increased by venous
hypertension secondary to blood stasis,11 and their activity is
inhibited by tissue inhibitors of MMPs (TIMPs). MMPeTIMP
imbalance has been observed in varicose disease,12 together
with collagen disruption, elastin loss and proliferation, rear-
rangement and migration into the intima of SMCs. SMCs in
varicose veins become dedifferentiated and lose their ability
to contract, while dysregulated apoptosis occurs. All these
phenomena contribute to venous dilation, venous relaxation
and loss of venous tone.
The triggers for such structural changes in the vein wall
remain unclear, although inflammatory events in venous
valves andwall are likely to be the initial culprits.7 The venous
leg system is subject to frequent postural pressure changes in
daily life. In particular, prolonged standing leads to pooling of
blood, which causes distension of veins and distortion of
venous valves. Leakage through such valves exposes endo-
thelial cells to flow reversal, which initiates endothelial and
leucocyte activation, the starting point of venous inflamma-
tion (Fig. 1).7 Repeated inflammatory stresses on the venous
endothelium lead to chronic recurring injury to the vein wall,
maintaining an inflammatory state at vein level.7
Evidence has accumulated in the past years that
inflammation could be key in wall remodelling, valve failure
and subsequent venous hypertension.8,11,13 Various types of
inflammatory mediators and growth factors are released,
including vascular cell adhesion molecule-1 (VCAM-1),
intercellular adhesion molecule-1 (ICAM-1), transforming
growth factor beta (TGF-b1), fibroblast growth factor beta
(FGF-b1) and vascular endothelial growth factor (VEGF). The
inflammatory cascades in the vein wall and venous valves
can cause progressive valvular incompetence and eventual
valvular destruction.13 Once initiated, venous valve damage
will be self-reinforcing, exacerbating venous hypertension
and disturbance of venous flow and causing further inflam-
mation (Fig. 2). As a result, reflux appears and may occur in
the superficial or deep venous system or in both.2 It is notFigure 1 Rolling and adhesion of leukocytes at the surface of
the endothelium, starting point of an inflammatory cascade
causing vein wall remodelling and eventually progression to
complications. Am J Pathol. 1983; 113:341e358. Copyright the
American Journal of Pathology.ascertained whether deep vein incompetence in primary
CVD is a congenital or acquired phenomenon.14
Capillary alteration
Venous hypertension increases hydrostatic pressure in
capillaries resulting in transcapillary filtration that exceeds
lymphatic flow. This contributes to the formation of inter-
stitial oedema. Venous hypertension alters blood flow in
capillaries, prompting leucocyte adhesion to capillary
endothelium and initiating an inflammatory reaction.15 One
theory holds that inflammation would open the gaps
between the endothelial cells via a mechanism involving
VEGF, nitric oxide synthetase (NOS) and the contraction of
actin and myosin filaments that are present in endothelial
cells.16 The gaps would become very large, greatly raising
capillary permeability to fluid, macromolecules and extra-
vasated red blood cells, resulting in their flow into the
interstitial space and in oedema formation. Based on the
observation that inter-endothelial gap junctions of capil-
laries from either the gaiter zone or thigh of CVI patients
were not widened, Pappas refuted this theory and proposed
an alternative explanation involving the formation of trans-
endothelial channels for macromolecule transport.17 Frag-
mentation and destruction of lymphatic vessels may further
impair drainage from the extremity, whereas dysfunction of
local nerve fibres may alter regulatory mechanisms (Fig. 3).2
Skin changes
Several mechanisms for the development of venous ulcera-
tion have been postulated, of which the theory of ‘leucocyte
trapping’ is the most likely,18 although challenged today. It is
hypothesised that the primary injury to the skin (which is the
final target of chronic venous hypertension) is extravasation
of macromolecules, such as fibrinogen and a-macroglobulin,
and red blood cells into the dermal interstitium. Red-blood-
cell-degradation products and extravasated interstitial
Figure 3 Venous hypertension is transmitted to the micro-
circulation and prompts leukocyte adhesion to capillary
endothelium. This initiates an inflammatory reaction which
dramatically increases capillary permeability. When trans-
capillary filtration exceeds lymphatic flow, an interstitial
edema occurs. Copyright Impact Me´decin.
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generate the initial inflammatory signal, which results in
leukocyte recruitment and migration into the dermis.17
Pathologic events occur during leucocyte migration into
thedermisand theendproduct of these isdermal fibrosis.One
of the pathologic events is an increase in TGF-b1 which is
either released by macrophages and mast cells or auto-
inducedbydermal fibroblasts. An increase inTGF-b1 causes an
imbalance in tissue remodelling, which results in increased
collagen synthesis and affects MMPs as well as TIMPs. It is
hypothesised that an imbalance in MMPs and their regulation
may cause or contribute to venous ulcer formation.17
A cascade of inflammatory events results in cutaneous
changes, which include skin hyperpigmentation caused by
haemosiderin deposition and eczematous dermatitis.
Fibrosis may develop in the dermis and subcutaneous tissue
(lipodermatosclerosis) (Fig. 4). There is an increased risk of
cellulitis and leg ulceration.2Figure 4 Early cellular events leading to the skin changes of
chronic venous insufficiencymay begin with venous hypertension
inducing low shear stress, which favors leukocyte adhesion and
spreading on the endothelium. Degranulation occurs as cyto-
plasmic granules containing proteolytic enzymes are released.
Subsequent tissue damagemay induce a secondary stimulation of
leukocytes and endothelial cells in the lipodermatosclerotic skin.There is some evidence that the severity of venous reflux
may be related to the risk of ulceration in CVI patients. A
linear relationship between ulceration rate and ambulatory
venous pressure has been shown.19Symptoms of CVD
Symptoms may accompany all stages of CVD. Pain in venous
disease is the chief complaint that leads to the diagnosis of
CVD. Current hypotheses on venous pain mechanisms focus
on a local inflammatory origin. It has been postulated that
pro-inflammatory mediators released locally by leucocytes
canactivatenociceptors located in the venouswall (between
endothelial cells and smooth muscle cells of the media) and
in the connective tissue that forms the perivenous space, in
close contact with the microcirculation.20 Unmyelinated C
fibres were identified in thewall of varicose veins, seemingly
arranged as a wide mesh arising from the adventitia and
spreading out into the external part of the media.21 Such
nervous fibres may play a key role in symptom onset.Implications for Treatment of CVD
Understanding of the pathophysiological processes suggests
potential therapeutic targets that could be effective not
only in relieving symptoms and signs of CVD but also in
slowing its progression.
Compression stockings improve venous haemodynamics,22
and reduce oedema.23 There is some evidence that surgery
aimed at preventing superficial venous reflux can aid in pre-
venting the recurrence of ulcers.24 On the other hand, and in
patients presenting with a combination of primary venous
obstruction and deep or superficial reflux, Raju et al. consider
that the treatment of obstruction alone by stent placement,
without correction of associated reflux, often provides satis-
factory relief rates.5,25 However, whatever the technique
used to heal or prevent an ulcer, it is not known how many
patients in C2, C3 or C4 (according to the CEAP classification)
must be treated to prevent the occurrence of a venous ulcer.
Therefore, cost-effectiveness studies on the techniques
described above have not been performed.
Treatment to inhibit inflammation may offer the great-
est opportunity to prevent disease-related complications.
Currently available medication such as VADs can attenuate
various features of the inflammatory cascade,2,7 particu-
larly the leucocyteeendothelium interactions that are
important in many aspects of the disease. These agents and
their mode of action deserve more detailed explanation.Introduction to VADs and their Mode of Action
VADs are a heterogeneous group of synthetic or plant-based
drugs (Table 2).26
Action of VADs on venous tone
Most VADs have been shown to increase venous tone by
a mechanism related to the noradrenaline pathway.27
Micronised purified flavonoid fraction (MPFF) prolongs
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blocking inactivation of noradrenaline and ruscus extracts
are agonists at venous a1-adrenergic receptors. A high
affinity for the venous wall was found for MPFF and
hydroxyethylrutosides. The precise mechanism by which
other drugs increase venous tone is not known.
Action of VADs on capillary resistance
Numerous studies have shown that VADs are able to
increase capillary resistance and reduce capillary filtra-
tion.27 This is seen for MPFF, rutosides, escin, ruscus
extracts, proanthocyanidines and calcium dobesilate. The
capillary protective effect of MPFF may be related to
inhibition of leucocyte adhesion to capillaries.
Action of VADs on lymphatic drainage
Theefficacyof coumarinon lymphoedemahas beendescribed
by Casley Smith.28 Coumarin alone or combined with rutin
improves lymph flow and reduces high-protein oedema by
stimulating proteolysis.27 MPFF improves lymphatic flow and
increases the number of lymphatic vessels, and calcium
dobesilate enhances lymphatic drainage.27
Action of VADs on haemorrheological disorders
Haemorrheological changes are constant in CVD, appearing
as a basic trait with increased blood viscosity due to plasma
volume reduction and increased fibrinogen as a conse-
quence of inflammation. The presence of huge red cell
aggregates in the vicinity of venules reduces blood flow and
impairs oxygen delivery from red cells. Erythrocyte
aggregability and blood viscosity increase with greater
severity of disease. Some VADs limit red cell aggregation
(Gingko biloba), decrease blood viscosity (MPFF and
calcium dobesilate) and increase red cell velocity (MPFF).27Table 2 Classification of the main venoactive drugs.26
Group Substance
Alpha-benzopyrones Coumarin
Gamma-benzopyrones
(flavonoids)
Diosmin
Micronized purified flavonoid fraction
Rutin and rutosides
0-(b-hydroxyethyl)-rutosides
(troxerutin, HR)
Saponins Escin
Ruscus extract
Other plant extracts Anthocyans
Proanthocyanidins (oligomers)
Extracts of Ginkgo, heptaminol and
troxerutin
Total triterpene fraction
Synthetic products Calcium dobesilate
Benzaron
NaftazonAction of VADs on inflammation
As described above in the section entitled ‘Pathophysiology
of primary CVD’, recent research has highlighted the
central role of inflammation and elucidated some processes
involved in the progression of CVD. Of all the currently
available drugs, only MPFF has shown an anti-inflammatory
effect in acute venous hypertension created by a venous
fistula in rats. In this model, MPFF treatment reduced reflux
flow in a dose-dependent manner. In animal models of
ischaemia/reperfusion, MPFF reduced the release of
inflammatory mediators such as oxygen free radicals,
prostaglandins and thromboxane.13
Therapeutic Efficacy of VADs
Effects of oral VADs on venous symptoms
The main indications for VADs are symptoms related to CVD
and oedema.29 A Cochrane review on VADs by Martinez
et al. examined the efficacy of such drugs in detail.30
Another Cochrane review of Pittler and Ernst was pub-
lished for escin only (horse chestnut seed extract, HCSE).31
Studies were classified as level A (low risk of bias), level B
(moderate risk of bias) or level C (high risk of bias). In the
review of 44 controlled studies versus placebo,30 the anal-
yses showed significant treatment benefits for the VADs
compared with placebo on pain, cramps, heaviness,
sensation of swelling and paraesthesia, despite the lack of
homogeneity between trials (Table 3). The only non-
significant effects were for itching, while for restless legs
the analyses showed significant benefit of VADs, with no
evidence of heterogeneity among studies. Tests of hetero-
geneity were not performed in the review by Pittler.31
Two randomised clinical trials were not included in the
review of VADs.30 One deals with MPFF,32 and the other is
a large study with calcium dobesilate,33 respectively, in 101
symptomatic patients and in 509 patients in CEAP classesOrigin
Melilot (Melilotus officinalis)
Woodruff (Asperula odorata)
Citrus spp. (Sophora japonica)
Rutaceae aurantiae
Sophora japonica
Eucalyptus spp.
Fagopyrum esculentum
Horse chestnut seed extracts (Aesculus hippocastanum L)
Butcher’s broom (Ruscus aculeatus)
Bilberry (Vaccinium myrtillus)
Red wine leaves extracts, Maritime pine (Pinus maritimus)
Ginkgo biloba
Centella asiatica
Synthetic
Synthetic
Synthetic
Table 3 Global results of combined analyses for all venoactive drugs, for all outcomes analysed as percentage of improved
patients, adapted from the Cochrane review of phlebotonics for venous insufficiency30 and the meta-analysis of adjunctive MPFF
on venous ulcer.39
Outcome variable N patients in
the Cochrane
review.30
N in
treatment
group
N in
placebo
group
Patients with
no symptom
(%) in Tt
group
Patients with
no symptom
(%) in
placebo group
Test for
treatment
effect
(P value)
Heterogeneity
of studies
Oedema 1245 626 619 59.4 42.5 5.81
(<.00001)
No
Trophic disorders 705 355 350 33.8 23.7 3.76
(<.0001)
No
Pain 2247 1294 953 63.4 37.0 4.70
(<.00001)
Yes
Cramps 1793 1072 721 67.6 45.5 3.02
(Z.003)
Yes
Restless legs 652 329 323 46.2 33.4 2.77
(Z.006)
No
Itching 405 206 199 64.6 41.2 .83 (NS) Yes
Heaviness 2166 1257 909 59.8 33.1 5.38
(<.00001)
Yes
Swelling 1072 544 528 62.9 38.4 3.86
(<.0001)
Yes
Paresthesias 1456 896 560 71.0 50.7 2.82
(Z.005)
Yes
N patients
in the
meta-analysis.39
N in
treatment
group
N in
control
group
Patients with
no ulcer (%)
in Tt group
Patients with
no ulcer (%) in
control group
Test for
overall
effect
(P value)
Heterogeneity
of studies
Venous ulcer
at month 6
616 318 298 61.3 47.7 .03 Yes
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and the placebo groups in the reduction of CVD-related
symptoms were recorded after a 2-month treatment with
MPFF (except for night cramps and oedema),32 or in QoL,
oedema and symptom severity at the end of the 3-month
treatment period with the calcium dobesilate.33 But
neither the aetiology (primary or secondary) nor the path-
ophysiological and anatomical anomalies of studied lower
limbs were reported in these two trials despite the CEAP
classification being available at the time, weakening the
valuability of such results.
On the basis of a large collection of publications including
Cochrane reviews, VADs, as a whole, were assigned a weak
recommendation in the improvement of symptoms and
oedema associated with CVD in the latest edition of the
Handbook of Venous Disorders.29 In the Siena consensus
paper on efficacy of VADs in symptom relief,34 data from
randomised, controlled trials (RCTs) were selected accord-
ing to the predefined criteria of evidence-based medicine
and on the basis of the experts’ own experience. Studies
were classified as grade A (at least two RCTs with large
sample sizes, meta-analyses combining homogeneous
results), grade B (RCTs with small sample size, single RCT) or
grade C (other controlled trials, non-RCTs). Outcomes
included only symptoms at any stage of the disease. In this
consensus document, a grade A was assigned to calcium
dobesilate, MPFF and O-(beta-hydroxyethyl)rutosides (HR)-oxerutins, a grade B to escin and ruscus extracts and a grade
C to the remaining VADs.
International guidelines on the management of CVD use
the same grading system as that of the Siena experts, except
formeta-analyses,whichwere gradeB.27Outcomes included
not only symptoms but also oedema and venous ulcer heal-
ing. When considering VADs, the guidelines largely summar-
ised and endorsed the positive findings of the recent
Cochrane reviews.30,31 The guidelines highlight the evidence
of efficacy of several VADs (calcium dobesilate, MPFF, ruto-
sides, HCSE, proanthocyanidines, escin, coumarin þ rutin
and synthetic products) in CVD-related oedema, and the
efficacy of MPFF as an adjunct to standard compression
treatment in the healing of venous ulcers. Given the consis-
tency of the evidence, a grade Awas assigned to three VADs:
calcium dobesilate, MPFF and HR-oxerutins for their effects
on symptoms, oedema and skin changes.27
No reservations were voiced regarding the safety of VADs,
except for coumarinerutin and benzarone (hepatotoxicity)
and for calcium dobesilate, with which some cases of tran-
sient agranulocytosis were reported from 1992 to 2005.27
Effect on venous oedema
Although oedema is a nonspecific sign, it is one of the most
frequent and typical signs in CVD. All other causes of
oedema should be excluded to confirm its venous origin.
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bilateral and is more frequently located at the ankle site.
Severalwell-conductedcontrolled trials versus placeboor
stockings have shown the efficacy of oral VADs such as MPFF,
rutosides, HCSE, calcium dobesilate, proanthocyanidines
(red grapevine leaves, or bark of maritime pine) and cou-
marinerutin.27,34 In these trials, the effect on oedema was
assessed objectively, using leg circumference measure-
ment, strain-gauge plethysmography and water displace-
ment. The analyses of a pool of 1245 patients of theCochrane
review,30 showed significant benefit of VADs in alleviating
oedema (Table 3).However, to theauthors’ knowledge, none
have considered which anatomical and pathophysiological
components the drugs act on and to what extent they
decrease the venous severity scoring (according to
Rutherford).35
Pharmacological treatment of leg ulcers
Among VADs, HCSE and hydroxyrutosides have not proven
superior to compression in advanced CVI,36 or in preventing
venous ulcer recurrence.37 Acceleration of the healing of
venous leg ulcers (stage C6 of the CEAP classification) has
been demonstrated by a double-blind study using micron-
ised purified flavonoid fraction (MPFF) in combination with
compression.38 This was confirmed in 2005 by a meta-
analysis of five trials with MPFF as an adjunct to standard
compression treatment in 723 patients in class C6,
according to the CEAP classification.39
Pentoxifylline, which is indicated in the management of
peripheral arterial disease, has also been used in the
management of venous leg ulcers. In a review of 12 clinical
trials involving 864 patients, pentoxifylline improved
venous ulcer healing on its own and when used in combi-
nation with compression compared with placebo.29,40
The last edition (3rd edition) of the Handbook of Venous
Disorders includes a chapter on drug treatment of varicose
veins, venous oedema and ulcers.29 The method of deter-
mining the strength and quality of the recommendations in
this document was based on the ‘Grading of Recommenda-
tions Assessment, Development and Evaluation’ (GRADE)
system,41 in which recommendations are accompanied by
a number (1 for ‘strong’ and 2 for ‘weak’ recommendation),
and a letter, which refers to the ‘quality of the evidence’
supporting the recommendation ranging from ‘A’ for highTable 4 Summary of tentative recommendations, according to
Indication Venoactive drug Re
Relief of symptoms associated
with CVD in patients C0s to
C6s and with CVD-related
edema
MPFF St
Rutosides St
Calcium dobesilate W
HCSE W
Ruscus extracts W
Healing of primary venous
ulcer, as an adjunct to
compressive and local
therapy (Coleridge Smith,
2009)29
MPFF St
HCSE: horse chestnut seed extract; MPFF: micronised purified flavonoquality to ‘B’ for moderate quality and ‘C’ for low quality of
evidence. The use of MPFF and of pentoxifylline in combi-
nation with compression in long-standing or large venous
ulcerswas assigned a ‘strong recommendationwith evidence
of moderate quality’ (Grade 1B).29 The evidence for
adjunctive MPFF or pentoxifylline treatment is based on the
meta-analyses, respectively by Coleridge Smith et al.,39 and
by Jull et al.40
Tentative Recommendation for VADs
Building on recent reviews and meta-analyses, tentative
recommendations for the use of VADs, based on the prin-
ciples of the GRADE system, were proposed. It should be
stressed that these recommendations reflect the opinions
and judgements of the authors, and have not been
endorsed by learned societies or other organisations.
These tentative recommendations are summarised in
Table 4. To our knowledge, no VAD has been evaluated in
a very large RCT of the type that could provide high-quality
evidence supporting their use in any indication related to
CVD. For MPFF and rutosides, there is substantial evidence
from smaller trials,42 supported by meta-analyses and, in
the case of MPFF, a large observational study,43 for their
efficacy in relieving CVD-related symptoms such as pain,
heaviness and cramps, and in reducing CVD-related lower
limb oedema. There are insufficient data to specify those
CEAP clinical classes for which the benefits will be great-
est, but it is reasonable to assume that patients at all
stages of the disease, and particularly at the early CEAP
stages, may benefit. There appear to be no important
safety concerns with the use of these drugs; hence, it is
possible to propose a strong recommendation, based on
evidence of moderate quality, for their use in these indi-
cations. HCSE and Ruscus extracts have also proven
effective against CVD-related symptoms and lower limb
oedema, although the volume and quality of evidence are
less than for the previous two drugs. In the apparent
absence of important safety concerns, these drugs may be
given a weak recommendation based on low-quality
evidence.
Calcium dobesilate has been associated with a potential
safety concern relating to rare cases of agranulocytosis.27
We consider that it is only possible to give a weak recom-
mendation for its use, given the uncertainty over thethe principles of the GRADE system.41
commendation for use Quality of evidence Code
rong Moderate 1B
rong Moderate 1B
eak Moderate 2B
eak Low 2C
eak Low 2C
rong Moderate 1B
id fraction.
124 M. Perrin, A.A. Rameletbalance between benefits and harms. Based on previous
guidelines,29 the use of MPFF in the healing of small
(5e10 cm2) venous ulcer can be given a strong recommen-
dation, based on evidence of moderate quality in ulcer of
primary aetiology (1B).
Key Questions to be Answered When Drawing
Up Future Guidelines in CVD
Studies of the efficacy of VADs in treating symptoms and
oedema related to CVD are rarely comparable, owing to
disparities in inclusion criteria and primary end points. The
effect of VADs on the natural history of CVD remains to be
determined. Prevention of CVD progression by inflamma-
tory pathway inhibition has been established in animal
models only, and must now be tested in patients.
Assessing the efficacy of treatment
An update of the ‘guidelines for testing drugs for CVD’44 is
needed to enable the pharmaceutical industry to invest the
resources required to perform large and definitive clinical
trials, with a view to improving the recommendations, which
are useful to clinicians and organisations involved in decision
making in this important field of CVD. Such guidelines could:
- Reiterate the basic principles that should prevail when
reporting (and setting up) a clinical trial, using the
Consolidated Standards of Reporting Trials (CONSORT)
statement; this CONSORT statement is designed to help
authors and investigators file reports, by the use of
a published checklist and a flow diagramme,45 available
on the Web site www.consort-statement.org.
- Describe patients comprehensively at study selection,
using the advancedCEAP classification, which implies that
not only the C of the CEAP should be completed but also
items E, A and P, together with mandatory duplex colour,
with or without plethysmography (level 2 investigation
according to Eklof et al.),4 and in certain cases, invasive
(level 3) investigation; the addition of the new descriptor
n for E, A and P items, when no venous abnormality is
identified, may be useful when describing patients with
leg complaints but no visible or detectable signs of CVD.4
- Promote the use of validated tools to assess symptoms,46
oedema47 and venous leg ulcer.48
- Have a consensus on a standard treatment for dressings,
compression therapy and local antiseptics in venous leg
ulcer.
Besides, there is a need for a consensus on the following
end points:
- Symptoms: How great does the decrease on the visual
analogue scale (VAS) scale have to be to consider there is
a clinical improvement?
- Oedema: How great does the reduction in ankle volume
have to be to consider it is clinically relevant?
- Varicose veins: Which criteria should be used to consider
a drug treatment for varicose veins as successful?
- Venous leg ulceration: When should we consider the
ulcer to be healed?Tools adapted to patient-reported outcome
Early stages of CVD are difficult to assess objectively,
particularly in C0s patients, as symptoms are by definition
subjective. The assessment of the patients’ perception of
their QoL is desirable in such cases. It is acknowledged that
both generic and specific QoL scales should be used: the
generic Short Form (12) Health Survey (SF-12) (or SF-36) is
a validated tool that could adopted, while for specific
scales, the Chronic Venous Disease Quality of Life Ques-
tionnaire (CIVIQ-20), which has been extensively vali-
dated,49 is the most often used in CVD, and is currently
validated in 13 languages.
On the other hand, the role of VADs in the prevention of
the natural history of CVD remains to be determined: are all
VADsable toprotectCVDpatients against diseaseprogression
to severe complications? Yet, the use of human-sized
experimental animals such as the pig allows for better eval-
uation of the key processes involved.50 It is to be hoped that
such models, together with future clinical research, will
accord pharmacological agents the role they deserve in the
management of CVD.Acknowledgements
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